CoChat
Sign Up
Cited by 83Breast Cancer Treatment StudiesBreast Lesions and CarcinomasMRI in cancer diagnosis

Prediction of pathological complete response and prognosis in patients with neoadjuvant treatment for triple-negative breast cancer

Open access
Gass, Paul, Lux, Michael P., Rauh, Claudia, Hein, Alexander, Bani, Mayada R., Fiessler, Cornelia, Hartmann, Arndt, Häberle, Lothar +7 more·2018·BMC Cancer
DOI 10.1186/s12885-018-4925-1PMC PMC6206705
Open this paper in CoChat — free accountOpen PDF

Abstract

It has been reported that pathological complete response is an important surrogate marker for disease-free survival and overall survival in patients with triple-negative breast cancer. This study investigates predictors of the response to neoadjuvant platinum-based or anthracycline-based treatment, and of the prognosis, in patients with triple-negative breast cancer. A total of 121 patients with triple-negative breast cancer received neoadjuvant treatment with either platinum or anthracycline between 2008 and 2013. Pathological complete response was assessed relative to different treatments using logistic regression models with age, clinical tumor stage, grading, and Ki-67 as predictors and interaction terms, to obtain adjusted and subgroup-specific results. The impact of the pathological complete response rate on disease-free survival and overall survival was also analyzed. The pathological complete response rate was higher after platinum/taxane treatment compared with anthracycline/taxane (50.0% vs. 41.8%), but this was not significant in the adjusted analysis (OR 1.44; 95% CI, 0.68 to 3.09). A high histological grade (G3) was a predictor for higher pathological complete response in platinum-based therapy (OR 2.27; 95% CI, 1.00 to 5.30). The effect of neoadjuvant chemotherapy on pathological complete response was significantly different for G1–2 vs. G3 ( P interaction = 0.013), and additional subgroup-specific differences were noted. Pathological complete response was a predictor for improved disease-free survival and overall survival in both treatment groups, with and without platinum chemotherapy. This retrospective study of patients with triple-negative breast cancer adds to the evidence that the treatment effect of platinum may be greatest particularly in G3 tumors. In addition, the effect of pathological complete response on the prognosis does not depend on the treatment used.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12885-018-4925-1

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 56

  1. [2]Perou CM Sorlie T Eisen MB van de Rijn M Jeffrey SS Rees CA Pollack JR Ross DT Johnsen H Akslen LA Molecular portraits of human breast tumours Nature 2000 406 6797 747 752 10.1038/35021093 10963602 · DOI
  2. [3]Perou C. M. Borresen-Dale A.-L. Systems Biology and Genomics of Breast Cancer Cold Spring Harbor Perspectives in Biology 2010 3 2 a003293 a003293 PMC3039533 21047916
  3. [4]Sorlie T Perou CM Tibshirani R Aas T Geisler S Johnsen H Hastie T Eisen MB van de Rijn M Jeffrey SS Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc Natl Acad Sci U S A 2001 98 19 10869 10874 10.1073/pnas.191367098 11553815 PMC58566 · DOI
  4. [5]Sotiriou C Neo SY McShane LM Korn EL Long PM Jazaeri A Martiat P Fox SB Harris AL Liu ET Breast cancer classification and prognosis based on gene expression profiles from a population-based study Proc Natl Acad Sci U S A 2003 100 18 10393 10398 10.1073/pnas.1732912100 12917485 PMC193572 · DOI
  5. [6]van ‘t Veer LJ Dai H van de Vijver MJ He YD Hart AA Mao M Peterse HL van der Kooy K Marton MJ Witteveen AT Gene expression profiling predicts clinical outcome of breast cancer Nature 2002 415 6871 530 536 10.1038/415530a 11823860 · DOI · Paper page
  6. [7]Schneeweiss A Lux MP Janni W Hartkopf AD Nabieva N Taran FA Overkamp F Kolberg HC Hadji P Tesch H Update breast cancer 2018 (part 2) – advanced breast cancer, quality of life and prevention Geburtshilfe Frauenheilkd 2018 78 3 246 259 10.1055/s-0044-101614 29576630 PMC5862553 · DOI
  7. [8]Untch M Huober J Jackisch C Schneeweiss A Brucker SY Dall P Denkert C Fasching PA Fehm T Gerber B Initial treatment of patients with primary breast cancer: evidence, controversies, consensus: spectrum of opinion of German specialists at the 15th international St. Gallen breast cancer conference (Vienna 2017) Geburtshilfe Frauenheilkd 2017 77 6 633 644 10.1055/s-0043-111601 28769126 PMC5489401 · DOI
  8. [9]Brenton JD Carey LA Ahmed AA Caldas C Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol 2005 23 29 7350 7360 10.1200/JCO.2005.03.3845 16145060 · DOI
  9. [10]Curigliano G Burstein HJ E PW Gnant M Dubsky P Loibl S Colleoni M Regan MM Piccart-Gebhart M Senn HJ De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen international expert consensus conference on the primary therapy of early breast cancer 2017 Ann Oncol 2017 28 8 1700 1712 10.1093/annonc/mdx308 28838210 PMC6246241 · DOI
  10. [11]Hammond ME Hayes DF Dowsett M Allred DC Hagerty KL Badve S Fitzgibbons PL Francis G Goldstein NS Hayes M American Society of Clinical Oncology/college of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer J Clin Oncol 2010 28 16 2784 2795 10.1200/JCO.2009.25.6529 20404251 PMC2881855 · DOI
  11. [12]Perou CM Molecular stratification of triple-negative breast cancers Oncologist 2011 16 Suppl 1 61 70 10.1634/theoncologist.2011-S1-61 21278442 · DOI
  12. [13]Prat A Adamo B Cheang MC Anders CK Carey LA Perou CM Molecular characterization of basal-like and non-basal-like triple-negative breast cancer Oncologist 2013 18 2 123 133 10.1634/theoncologist.2012-0397 23404817 PMC3579595 · DOI
  13. [14]Denkert C Liedtke C Tutt A von Minckwitz G Molecular alterations in triple-negative breast cancer-the road to new treatment strategies Lancet 2017 389 10087 2430 2442 10.1016/S0140-6736(16)32454-0 27939063 · DOI
  14. [15]Wolff AC Hammond ME Hicks DG Dowsett M McShane LM Allison KH Allred DC Bartlett JM Bilous M Fitzgibbons P Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update J Clin Oncol 2013 31 31 3997 4013 10.1200/JCO.2013.50.9984 24101045 · DOI
  15. [16]Bareche Y Venet D Ignatiadis M Aftimos P Piccart M Rothe F Sotiriou C Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis Ann Oncol 2018 29 4 895 902 10.1093/annonc/mdy024 29365031 PMC5913636 · DOI
  16. [17]Mancini P Angeloni A Risi E Orsi E Mezi S Standard of care and promising new agents for triple negative metastatic breast cancer Cancers 2014 6 4 2187 2223 10.3390/cancers6042187 25347122 PMC4276962 · DOI
  17. [18]Bertucci F Finetti P Birnbaum D Mamessier E The PD1/PDL1 axis, a promising therapeutic target in aggressive breast cancers Oncoimmunology 2016 5 3 e1085148 10.1080/2162402X.2015.1085148 27141340 PMC4839307 · DOI
  18. [19]Lord CJ Ashworth A PARP inhibitors: synthetic lethality in the clinic Science 2017 355 6330 1152 1158 10.1126/science.aam7344 28302823 PMC6175050 · DOI
  19. [20]Farmer H McCabe N Lord CJ Tutt AN Johnson DA Richardson TB Santarosa M Dillon KJ Hickson I Knights C Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy Nature 2005 434 7035 917 921 10.1038/nature03445 15829967 · DOI · Paper page
  20. [21]Timms KM Abkevich V Hughes E Neff C Reid J Morris B Kalva S Potter J Tran TV Chen J Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes Breast Cancer Res 2014 16 6 475 10.1186/s13058-014-0475-x 25475740 PMC4308910 · DOI
  21. [22]Lux MP Janni W Hartkopf AD Nabieva N Taran FA Overkamp F Kolberg HC Hadji P Tesch H Ettl J Update breast cancer 2017 - implementation of novel therapies Geburtshilfe Frauenheilkd 2017 77 12 1281 1290 10.1055/s-0043-122885 29269955 PMC5734938 · DOI
  22. [23]Fasching PA Ekici AB Wachter DL Hein A Bayer CM Haberle L Loehberg CR Schneider M Jud SM Heusinger K Breast cancer risk - from genetics to molecular understanding of pathogenesis Geburtshilfe Frauenheilkd 2013 73 12 1228 1235 10.1055/s-0033-1360178 24771903 PMC3964347 · DOI
  23. [24]Couch FJ Hart SN Sharma P Toland AE Wang X Miron P Olson JE Godwin AK Pankratz VS Olswold C Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer J Clin Oncol 2015 33 4 304 311 10.1200/JCO.2014.57.1414 25452441 PMC4302212 · DOI
  24. [25]Liedtke C Mazouni C Hess KR Andre F Tordai A Mejia JA Symmans WF Gonzalez-Angulo AM Hennessy B Green M Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer J Clin Oncol 2008 26 8 1275 1281 10.1200/JCO.2007.14.4147 18250347 · DOI · Paper page
  25. [26]von Minckwitz G Untch M Blohmer JU Costa SD Eidtmann H Fasching PA Gerber B Eiermann W Hilfrich J Huober J Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes J Clin Oncol 2012 30 15 1796 1804 10.1200/JCO.2011.38.8595 22508812 · DOI · Paper page
  26. [27]Hahnen E Lederer B Hauke J Loibl S Krober S Schneeweiss A Denkert C Fasching PA Blohmer JU Jackisch C Germline mutation status, pathological complete response, and disease-free survival in triple-negative breast cancer: secondary analysis of the GeparSixto randomized clinical trial JAMA Oncol 2017 3 10 1378 1385 10.1001/jamaoncol.2017.1007 28715532 PMC5710508 · DOI
  27. [28]Sikov WM Berry DA Perou CM Singh B Cirrincione CT Tolaney SM Kuzma CS Pluard TJ Somlo G Port ER Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance) J Clin Oncol 2015 33 1 13 21 10.1200/JCO.2014.57.0572 25092775 PMC4268249 · DOI
  28. [29]Byrski T Gronwald J Huzarski T Grzybowska E Budryk M Stawicka M Mierzwa T Szwiec M Wisniowski R Siolek M Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy J Clin Oncol 2010 28 3 375 379 10.1200/JCO.2008.20.7019 20008645 · DOI
  29. [30]von Minckwitz G, Timms K, Untch M, Elkin EP, Hahnen E, Fasching PA, Schneeweiss A, Salat CT, Rezai M, Blohmer J-U, Zahm D-M, Jackisch C, Gerber B, Klare P, Kümmel S, Paepke S, Schmutzler R, Chau S, Reid J, Hartman A-R, Nekljudova V, Weber KE, Loibl S. Homologous repair deficiency (HRD) as measure to predict the effect of carboplatin on survival in the neoadjuvant phase II trial GeparSixto in triple-negativeearly breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium. Cancer Res. 2017;77(4 Suppl):Abstract nr P1-09-02.
  30. [33]Silver DP Richardson AL Eklund AC Wang ZC Szallasi Z Li Q Juul N Leong CO Calogrias D Buraimoh A Efficacy of neoadjuvant cisplatin in triple-negative breast cancer J Clin Oncol 2010 28 7 1145 1153 10.1200/JCO.2009.22.4725 20100965 PMC2834466 · DOI
  31. [34]Gluz Oleg Nitz Ulrike Liedtke Cornelia Christgen Matthias Grischke Eva-Maria Forstbauer Helmut Braun Michael Warm Mathias Hackmann John Uleer Christoph Aktas Bahriye Schumacher Claudia Bangemann Nikola Lindner Christoph Kuemmel Sherko Clemens Michael Potenberg Jochem Staib Peter Kohls Andreas von Schumann Raquel Kates Ronald Kates Ronald Schumacher Johannes Wuerstlein Rachel Kreipe Hans Heinrich Harbeck Nadia Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial Results JNCI: Journal of the National Cancer Institute 2017 110 6 628 637 10.1093/jnci/djx258 29228315 · DOI
  32. [35]von Minckwitz G Schneeweiss A Loibl S Salat C Denkert C Rezai M Blohmer JU Jackisch C Paepke S Gerber B Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial Lancet Oncol 2014 15 7 747 756 10.1016/S1470-2045(14)70160-3 24794243 · DOI
  33. [37]Zhang J Powell SN The role of the BRCA1 tumor suppressor in DNA double-strand break repair Mol Cancer Res 2005 3 10 531 539 10.1158/1541-7786.MCR-05-0192 16254187 · DOI
  34. [38]Bhattacharyya A Ear US Koller BH Weichselbaum RR Bishop DK The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin J Biol Chem 2000 275 31 23899 23903 10.1074/jbc.C000276200 10843985 · DOI
  35. [39]Beheshti F Hassanian SM Khazaei M Hosseini M ShahidSales S Hasanzadeh M Maftouh M Ferns GA Avan A Genetic variation in the DNA repair pathway as a potential determinant of response to platinum-based chemotherapy in breast cancer J Cell Physiol 2018 233 4 2752 2758 10.1002/jcp.26091 28696006 · DOI
  36. [40]Sharma P, Barlow WE, Godwin AK, Pathak H, Isakova K, Williams D, Timms KM, Hartman AR, Wenstrup RJ, Linden HM, et al. Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with doxorubicin-based adjuvant chemotherapy (SWOG S9313). Ann Oncol. 2018;29(3):654–60. PMC5888953 29293876
  37. [41]Telli Melinda L. Hellyer Jessica Audeh William Jensen Kristin C. Bose Shikha Timms Kirsten M. Gutin Alexander Abkevich Victor Peterson Rebecca N. Neff Chris Hughes Elisha Sangale Zaina Jones Joshua Hartman Anne-Renee Chang Pei-Jen Vinayak Shaveta Wenstrup Richard Ford James M. Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer Breast Cancer Research and Treatment 2017 168 3 625 630 10.1007/s10549-017-4624-7 29275435 · DOI
  38. [42]Zhao EY Shen Y Pleasance E Kasaian K Leelakumari S Jones M Bose P Ch'ng C Reisle C Eirew P Homologous recombination deficiency and platinum-based therapy outcomes in advanced breast cancer Clin Cancer Res 2017 23 24 7521 7530 10.1158/1078-0432.CCR-17-1941 29246904 · DOI
  39. [43]Beckmann MW Brucker C Hanf V Rauh C Bani MR Knob S Petsch S Schick S Fasching PA Hartmann A Quality assured health care in certified breast centers and improvement of the prognosis of breast cancer patients Onkologie 2011 34 7 362 367 10.1159/000329601 21734422 · DOI
  40. [44]Kowalski C Ferencz J Brucker SY Kreienberg R Wesselmann S Quality of care in breast cancer centers: results of benchmarking by the German cancer society and German society for breast diseases Breast 2015 24 2 118 123 10.1016/j.breast.2014.11.014 25515645 · DOI
  41. [45]Elston CW Ellis IO Pathological prognostic factors in breast cancer. I. the value of histological grade in breast cancer: experience from a large study with long-term follow-up Histopathology 1991 19 5 403 410 10.1111/j.1365-2559.1991.tb00229.x 1757079 · DOI
  42. [46]Fasching PA Heusinger K Haeberle L Niklos M Hein A Bayer CM Rauh C Schulz-Wendtland R Bani MR Schrauder M Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment BMC Cancer 2011 11 486 10.1186/1471-2407-11-486 22081974 PMC3262864 · DOI
  43. [47]Sauter G Lee J Bartlett JM Slamon DJ Press MF Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations J Clin Oncol 2009 27 8 1323 1333 10.1200/JCO.2007.14.8197 19204209 · DOI
  44. [48]Telli ML Timms KM Reid J Hennessy B Mills GB Jensen KC Szallasi Z Barry WT Winer EP Tung NM Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer Clin Cancer Res 2016 22 15 3764 3773 10.1158/1078-0432.CCR-15-2477 26957554 PMC6773427 · DOI · Paper page
  45. [49]von Wahlde MK Timms KM Chagpar A Wali VB Jiang T Bossuyt V Saglam O Reid J Gutin A Neff C Intratumor heterogeneity of homologous recombination deficiency in primary breast cancer Clin Cancer Res 2017 23 5 1193 1199 10.1158/1078-0432.CCR-16-0889 27601588 · DOI
  46. [51]Denkert C von Minckwitz G Brase JC Sinn BV Gade S Kronenwett R Pfitzner BM Salat C Loi S Schmitt WD Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers J Clin Oncol 2015 33 9 983 991 10.1200/JCO.2014.58.1967 25534375 · DOI
  47. [52]Tun N Villani G Ong K Yoe L Bo Z Risk of having BRCA1 mutation in high-risk women with triple-negative breast cancer: a meta-analysis Clin Genet 2014 85 1 43 48 10.1111/cge.12270 24000781 · DOI
  48. [53]Mavaddat N Barrowdale D Andrulis I Domchek S Eccles D Nevanlinna H Ramus S Spurdle A Robson M Sherman M HEBON; EMBRACE; GEMO study collaborators; kCon-fab investigators; SWE-BRCA collaborators; consortium of investigators of modifiers of BRCA1/2. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the consortium of investigators of modifiers of BRCA1/2 (CIMBA) Cancer Epidemiol Biomark Prev 2012 21 134 147 10.1158/1055-9965.EPI-11-0775 PMC3272407 22144499 · DOI
  49. [54]Krammer J Pinker-Domenig K Robson ME Gonen M Bernard-Davila B Morris EA Mangino DA Jochelson MS Breast cancer detection and tumor characteristics in BRCA1 and BRCA2 mutation carriers Breast Cancer Res Treat 2017 163 3 565 571 10.1007/s10549-017-4198-4 28343309 PMC5490380 · DOI
  50. [55]Davies H Glodzik D Morganella S Yates LR Staaf J Zou X Ramakrishna M Martin S Boyault S Sieuwerts AM HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures Nat Med 2017 23 4 517 525 10.1038/nm.4292 28288110 PMC5833945 · DOI · Paper page
  51. [56]Chen X He C Han D Zhou M Wang Q Tian J Li L Xu F Zhou E Yang K The predictive value of Ki-67 before neoadjuvant chemotherapy for breast cancer: a systematic review and meta-analysis Future Oncol 2017 13 9 843 857 10.2217/fon-2016-0420 28075166 · DOI
  52. [57]Balmativola D Marchio C Maule M Chiusa L Annaratone L Maletta F Montemurro F Kulka J Figueiredo P Varga Z Pathological non-response to chemotherapy in a neoadjuvant setting of breast cancer: an inter-institutional study Breast Cancer Res Treat 2014 148 3 511 523 10.1007/s10549-014-3192-3 25395316 PMC4243004 · DOI
  53. [58]Vörös A Csörgő E Kővári B Lázár P Kelemen G Rusz O Nyári T Cserni G Different methods of pretreatment Ki-67 labeling index evaluation in core biopsies of breast cancer patients treated with neoadjuvant chemotherapy and their relation to response to therapy Pathol Oncol Res 2015 21 1 147 155 10.1007/s12253-014-9800-z 24859973 · DOI
  54. [59]Würfel F Erber R Hübner H Hein A Lux M Jud S Kremer A Kranich H Mackensen A Häberle L TILGen: a program to investigate immune targets in breast cancer patients - first results on the influence of tumor-infiltrating lymphocytes Breast Care 2018 13 8 14 10.1159/000486949 29950961 PMC6016056 · DOI
  55. [60]Nitiss JL Targeting DNA topoisomerase II in cancer chemotherapy Nat Rev Cancer 2009 9 5 338 350 10.1038/nrc2607 19377506 PMC2748742 · DOI
  56. [61]Misteli T Soutoglou E The emerging role of nuclear architecture in DNA repair and genome maintenance Nat Rev Mol Cell Biol 2009 10 4 243 254 10.1038/nrm2651 19277046 PMC3478884 · DOI

Cited by

Sorted by citations

Authors
Gass, P., Lux, M. P., Rauh, C., Hein, A., Bani, M. R., Fiessler, C., Hartmann, A., Häberle, L., Pretscher, J., Erber, R., Wachter, D. L., Schulz-Wendtland, R., Beckmann, M. W., Fasching, P. A., & Wunderle, M.
Affiliations
Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
Corresponding author
Gass, Paul
ORCID
Venue
BMC Cancer
Publisher
Springer Science and Business Media LLC
Published
2018-10-29
Volume
18
Issue
1
Pages
1051-1051
ISSN
1471-2407 (ISSN-L)
DOI
10.1186/s12885-018-4925-1
PMC
PMC6206705
OpenAlex
W2898793465
Cited by
83
References
1
Citations by year
2026: 7 · 2025: 9 · 2024: 10 · 2023: 13 · 2022: 12 · 2021: 9 · 2020: 15 · 2019: 8
FWCI
2.42
Type
journal article
Language
en
Open access
Licence
Locations
  • BMC Cancer (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • OPUS Repository (Kooperativer Bibliotheksverbund Berlin-Brandenburg) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Deutsche Forschungsgemeinschaft
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Breast Lesions and Carcinomas
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › MRI in cancer diagnosis
Keywords
triple-negative breast cancer, neoadjuvant chemotherapy, pathological complete response, platinum-based chemotherapy, anthracycline chemotherapy, taxanes, histological grade, Ki-67, disease-free survival, overall survival, prognostic factors, predictors of treatment response
MeSH terms
Adult, Aged, Female, Humans, Middle Aged, Neoplasm Staging, Prognosis, Retrospective Studies, Odds Ratio, Treatment Outcome, Neoadjuvant Therapy, Kaplan-Meier Estimate, Neoplasm Grading, Triple Negative Breast Neoplasms

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review